[Ip-health] Note on use of Orphan Drug Act to increase price of hydroxyprogesterone caproate from $10 to $1, 500 per dose
james.love at keionline.org
Tue Mar 22 04:39:55 PDT 2011
This concerns an increase in the price of hydroxyprogesterone
caproate, from $10 to $20 per dose to $1,500 per dose. Long used off
label to prevent premature births, the drug will be sold by KV
Pharmaceuticals, under a new legal monopoly, at 150 times the price of
the generic product. using the trade name Makena.
Following a letter from U.S. Sen. Sherrod Brown (D-OH) and U.S. Sen.
Amy Klobuchar (D-MN) to the FTC, there have been news reports about
the price hike, including by Bloomberg, Time, TechDirt, the WSJ, the
LA Times, ABC and the Associated Press, as well as many other news
The KEI note below provides links to news stories and a copy of
Senator Sherrod Brown's press release, as well as details of the legal
mechanism that created the monopoly (the Orphan Drug Act), and data
from ClinicialTrials.Gov and the NIH RePORTER database regarding the
relative roles of the KV Pharmaceuticals and other parties, including
the NIH, in funding and carrying out research on hydroxyprogesterone
Note on use of Orphan Drug Act to increase price of
hydroxyprogesterone caproate from $10 to $1,500 per dose
James Love. Knowledge Ecology International
http://www.keionline.org, +1.202.332.2670, US Mobile: +1.202.361.3040,
Geneva Mobile: +41.76.413.6584, efax: +1.888.245.3140.
More information about the Ip-health